Masters of Longevity - The Pulse

PR Newswire19 Jun 2026
AIGelatin Market worth $6.43 billion by 2031- Exclusive Report by MarketsandMarkets™ (PR Newswire)

Gelatin Market worth $6.43 billion by 2031- Exclusive Report by MarketsandMarkets™

Market outlook for gelatin covering growth drivers, source and application trends, regional demand, and major supplier landscape.

Key takeaways
  • Gelatin market is projected to reach USD 6.43 billion by 2031.
  • Health and nutrition segment is forecast to grow at 7.7% CAGR.
  • Marine gelatin is the fastest-growing source due to Halal and Kosher suitability.
Longevity Technology19 Jun 2026
AICambrian Bio reports positive early human trial results for prediabetes drug (Longevity Technology)

Cambrian Bio reports positive early human trial results for prediabetes drug

Prediabetes drug development: a look at early human study findings and the sponsor’s planned follow‑up trials, highlighting potential metabolic implications.

Key takeaways
  • ATX-304 raised plasma adiponectin and lowered triglycerides with p<0.01 significance.
  • Resting metabolic rate increased by 8% with minimal weight loss at tested exposure.
  • MRI-PDFF showed significant decreases in liver fat and visceral adipose tissue.
Science Daily - Health & Medicine19 Jun 2026
Scientists May Have Found What Really Triggers Alzheimer’s Disease (Science Daily - Health & Medicine)

Scientists May Have Found What Really Triggers Alzheimer’s Disease

A new paper proposes a unifying theory that challenges plaque-first thinking about what initiates Alzheimer’s disease.

Key takeaways
  • Disruption of neuronal microtubules may initiate the cascade linking amyloid-beta and tau pathologies.
  • Microtubule instability can explain how amyloid-beta and tau reciprocally accelerate neurodegeneration.
  • Therapies stabilizing microtubules or preventing their disruption could offer earlier disease intervention.
Longevity Technology19 Jun 2026
AIBPGbio advances potential first-ever treatment for primary CoQ10 deficiency (Longevity Technology)

BPGbio advances potential first-ever treatment for primary CoQ10 deficiency

Report on clinical and preclinical data presented at a mitochondrial medicine meeting evaluating a novel mitochondrial therapy for primary CoQ10 deficiency.

Key takeaways
  • No FDA-approved therapies exist for primary CoQ10 deficiency.
  • Mouse disease models showed BPM31510 increased CoQ levels in brain and kidney.
  • In four pediatric compassionate-use cases, BPM31510 was well tolerated and improved ataxia within four weeks.